CA2671697A1 - Use of il-27 agonists to reduce immune mediated abortion - Google Patents

Use of il-27 agonists to reduce immune mediated abortion Download PDF

Info

Publication number
CA2671697A1
CA2671697A1 CA002671697A CA2671697A CA2671697A1 CA 2671697 A1 CA2671697 A1 CA 2671697A1 CA 002671697 A CA002671697 A CA 002671697A CA 2671697 A CA2671697 A CA 2671697A CA 2671697 A1 CA2671697 A1 CA 2671697A1
Authority
CA
Canada
Prior art keywords
subject
sample
protein
agonist
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002671697A
Other languages
English (en)
French (fr)
Inventor
Odile Devergne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2671697A1 publication Critical patent/CA2671697A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002671697A 2006-12-07 2007-12-05 Use of il-27 agonists to reduce immune mediated abortion Abandoned CA2671697A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86903506P 2006-12-07 2006-12-07
US60/869,035 2006-12-07
PCT/US2007/024869 WO2008070097A1 (en) 2006-12-07 2007-12-05 Use of il-27 agonists to reduce immune mediated abortion

Publications (1)

Publication Number Publication Date
CA2671697A1 true CA2671697A1 (en) 2008-06-12

Family

ID=39185969

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002671697A Abandoned CA2671697A1 (en) 2006-12-07 2007-12-05 Use of il-27 agonists to reduce immune mediated abortion

Country Status (6)

Country Link
US (1) US20100150862A1 (https=)
EP (1) EP2091555A1 (https=)
JP (2) JP2010511710A (https=)
CA (1) CA2671697A1 (https=)
MX (1) MX2009006091A (https=)
WO (1) WO2008070097A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007298571B2 (en) 2006-09-22 2012-06-07 St. Jude Children's Research Hospital Modulating regulatory T cell activity via Interleukin 35
WO2011028390A1 (en) * 2009-08-24 2011-03-10 St. Jude Children's Research Hospital Compositions and methods for potentiating interleukin-35
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
US20130183326A9 (en) 2009-11-20 2013-07-18 St. Jude Children's Research Hospital Methods and compositions for modulating the activity of the interleukin-35 receptor complex
US8691227B2 (en) 2009-12-17 2014-04-08 Merck Sharp & Dohme Corp. Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
EP2687851A1 (en) * 2012-07-20 2014-01-22 Matricelab Innove Method for increasing implantation success in assisted fertilization
BR112015026019A2 (pt) * 2013-04-11 2017-07-25 Brigham & Womens Hospital Inc métodos e composições de tratamento de doenças autoimunes
US12404494B2 (en) 2019-10-15 2025-09-02 Spinalcyte, Llc Prevention of recurrent miscarriages through administration of fibroblasts and fibroblast-educated paternal cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830451A (en) * 1996-07-19 1998-11-03 Brigham & Women's Hospital, Inc. Haematopoietic cytokine Epstein Barr virus-induced protein
EP2441465B1 (en) * 2003-10-24 2014-01-15 Nora Therapeutics, Inc. Compositions and methods for healthy pregnancy

Also Published As

Publication number Publication date
JP2010511710A (ja) 2010-04-15
MX2009006091A (es) 2009-08-18
WO2008070097A1 (en) 2008-06-12
US20100150862A1 (en) 2010-06-17
JP2013018794A (ja) 2013-01-31
EP2091555A1 (en) 2009-08-26

Similar Documents

Publication Publication Date Title
US20100150862A1 (en) Methods of modulating maternal-fetal tolerance
JP4833850B2 (ja) Ｉｌ−１７活性阻害による多発性硬化症を治療するための方法
Dimitriadis et al. Cytokines, chemokines and growth factors in endometrium related to implantation
RU2426742C2 (ru) Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами
Iijima et al. Infiltrating CD8+ T cells in oral lichen planus predominantly express CCR5 and CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP-10/CXCL10 in their cytolytic granules: a potential self-recruiting mechanism
Cooper et al. IL-1 activity is reduced in psoriatic skin. Decreased IL-1 alpha and increased nonfunctional IL-1 beta.
Dinarello Biologic basis for interleukin-1 in disease
US20070224166A1 (en) Uses of mammalian cytokine; related reagents
ES2975739T3 (es) Uso terapéutico de inhibidores de la activación o estimulación de células T
JP6744391B2 (ja) Ｔｏｓｏ活性を調節するための方法および組成物
AU2005316405A1 (en) Methods for treating autoimmune disorders
JP2007510639A (ja) 炎症性腸疾患の治療方法
UA129672C2 (uk) Антитіло до trem-1 та його застосування
US12527875B2 (en) Methods for treating graft versus host disease
US8795656B2 (en) Methods of treating rheumatoid arthritis by administering an anti-IL3 antibody
TW202106712A (zh) 類風溼性關節炎之診斷及治療方法
EP1879604B1 (en) Pif tetrapeptides
KR20070084407A (ko) 인터루킨-21의 항원성 에피토프, 관련된 항체 및 의료분야에서 이들의 용도
NZ547139A (en) Use of preimplantation factor peptides to treat intolerence to embryo implantation
ZA200509143B (en) GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
CA2539477A1 (en) Treatment and diagnosis of a reproductive disorder by measuring or inhibiting interferon-.gamma.
Bellissimo et al. Maternal obesogenic diet disrupts mid-gestation decidual immune and vascular homeostasis without impairing spiral artery remodelling
Gibson Expression of the [alpha] E [beta] 7 integrin by mast cells in rheumatoid synovium
CN101024089A (zh) E4bp4基因在胚胎着床过程中的功能及其应用
Farine Mechanisms responsible for the activation of maternal peripheral leukocytes during term labour

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20141205